Your session is about to expire
← Back to Search
Targeted Therapy
Genomic Testing-Based Targeted Therapy for Cancer
Phase 2
Recruiting
Led By RACHEL MILLER, MD
Research Sponsored by Rachel Miller
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must have failed first-line therapy for their disease (refractory) or have no options for curative therapies
Patients with brain metastasis must have had treatment of their brain metastasis completed at least 1 day prior to enrollment and be on stable dose of steroids or off steroids at the time of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial is testing whether a targeted therapy based on genomic analysis can improve progression-free survival in cancer patients.
Who is the study for?
Adults (18+) with solid or blood cancers, who've had genetic testing on their tumors and failed first-line therapy, can join this trial. They must be able to sign consent and have measurable disease. Excluded are pregnant women, HIV patients not stable on antiretroviral therapy, those with uncontrolled illnesses or recent chemo/radiotherapy.Check my eligibility
What is being tested?
The study tests targeted therapies chosen based on tumor genetic analysis by the Markey Cancer Center Molecular Tumor Board. It aims to see if these treatments improve the time patients live without cancer progression compared to previous therapies they've tried.See study design
What are the potential side effects?
Potential side effects depend on the specific targeted therapy given but may include reactions at the infusion site, fatigue, nausea, skin changes, and an increased risk of infections due to immune system effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My first treatment didn’t work or there are no treatments that can cure my disease.
Select...
I have completed treatment for brain metastasis and am not on increasing doses of steroids.
Select...
I am capable of limited self-care and spend less than half of my day in bed.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression Free Survival
Trial Design
1Treatment groups
Experimental Treatment
Group I: Therapeutic InterventionExperimental Treatment1 Intervention
Therapeutic Intervention
Find a Location
Who is running the clinical trial?
Rachel MillerLead Sponsor
3 Previous Clinical Trials
48 Total Patients Enrolled
RACHEL MILLER, MDPrincipal InvestigatorUniversity of Kentucky
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't had chemotherapy or radiotherapy in the last 3 weeks, or 6 weeks for specific drugs, and have recovered from any side effects.I do not have any severe illnesses that my doctor thinks could interfere with the treatment.I am HIV positive with a CD4 count above 500 and on stable antiretroviral therapy for over a month.My first treatment didn’t work or there are no treatments that can cure my disease.My cancer can be measured by tests or seen on scans.I have completed treatment for brain metastasis and am not on increasing doses of steroids.I am capable of limited self-care and spend less than half of my day in bed.I am 18 years old or older.My cancer is being or will be genetically tested.
Research Study Groups:
This trial has the following groups:- Group 1: Therapeutic Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has the Therapeutic Intervention been validated by the FDA?
"Our staff at Power assessed Therapeutic Intervention's safety as a 2 because it is currently in Phase 2 and has some evidence of its security but none to prove efficacy."
Answered by AI
Is there still capacity for participants in this clinical research?
"The clinical trial is actively enrolling participants, evidenced by its presence on the official database. It was published initially in April of 2017 and last modified in November of 2022."
Answered by AI
What is the current sample size of this medical experiment?
"Indeed, the information hosted on clinicaltrials.gov testifies that this medical study is currently searching for potential participants. Published in April 2017 and amended most recently in November 2022, 93 individuals are needed from 1 site to complete the trial."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger